JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer
Received Date : 28 Sep 2020
Accepted Date : 30 Mar 2021
Available Online : 14 Apr 2021
Doi: 10.37047/jos.2020-79256 - Article's Language: EN
J Oncol Sci. 2021;7(2):42-9
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: Neoadjuvant chemotherapy (NAC) is a widely used treatment modality for breast cancer and may delay surgery for unresponsive patients. The objective of this study was to determine the predictive factors for complete pathological response and survival after NAC for the most appropriate patient selection before treatment. Material and Methods: Records of breast cancer patients with NAC between 2011 and 2015 were reviewed retrospectively. Statistical analysis was done using SPSS version 20.0 (SPSS Inc., Chicago, Illinois). Results: Twenty-six patients (22.6%) showed pathological Miller Payne Grade 5 response (T0), and three patients showed no measurable tumor, residue with separate tumor cells (T1 mi). The presence of HER2-neu expression (p=0.03), absence of estrogen receptor (ER) and progesterone receptor (PR) expression (p=0.001), and high histological grade (p=0.025) were found associated with complete pathological response. Tumor diameter and lymphoid infiltration showed no correlation with complete pathological response. Also, we found that patients who showed lower pathological nodal stage according to American Joint Committee on Cancer (AJCC), 8th edition had statistically significant longer survival period (p<0.05), but Miller-Payne Grade 5 response could not predict survival results [p=0.814 for overall survival (OS) and p=0.295 for progression-free survival (PFS)]. Conclusion: Neoadjuvant treatment would be more effective in tumors with ER-negative, HER-2 positive, and high-grade properties. Survival effect might be predicted earlier with pathologic nodal results according to AJCC cancer staging system, 8th edition.
KAYNAKLAR
  1. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49(8):1996-2001. [PubMed] 
  2. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2): 93-99. [Crossref]  [PubMed] 
  3. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary che motherapy: prognostic significance and survival. Breast. 2003;12(5):320-327. [Crossref]  [PubMed] 
  4. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11(6):574-589. [Crossref]  [PubMed] 
  5. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2008;17(4):301-311. [Crossref]  [PubMed] 
  6. Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park). 1997;11(6 Suppl 6):37-40. [PubMed] 
  7. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95(4): 681-695. [Crossref]  [PubMed] 
  8. Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434-1442. [Crossref]  [PubMed] 
  9. Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Molecular classification of breast carcinoma: From traditional, old-fashioned way to a new age, and a new way. J Breast Health. 2015;11(2):59-66. [Crossref]  [PubMed]  [PMC] 
  10. Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29(28):3739-3746. [Crossref]  [PubMed]  [PMC] 
  11. Fernández-Sánchez M, Gamboa-Dominguez A, Uribe N, et al. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol. 2006;23(2):171-183. [Crossref]  [PubMed] 
  12. Lin Q, Liu Y, Chen H, Liu Y, Tang Q, Liu J, et al. Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer. Mol Clin Oncol. 2013;1(5):839-844. [Crossref]  [PubMed]  [PMC] 
  13. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739-749. [Crossref]  [PubMed] 
  14. Yu Y, Xiang H, He XM, Yang HJ, Zong XY. Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience. Asian Pac J Cancer Prev. 2013;14(4):2401-2406. [Crossref]  [PubMed] 
  15. Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2011;67(4):911-917. [Crossref]  [PubMed] 
  16. Sánchez-Mu-oz A, Plata-Fernández YM, Fernández M, et al. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. Clin Breast Cancer. 2013;13(2):146-152. [Crossref]  [PubMed] 
  17. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357. [Crossref]  [PubMed] 
  18. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297-306. [PubMed] 
  19. Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007;50(4):409-417. [Crossref]  [PubMed] 
  20. Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. Breast Cancer Res Treat. 2016;160(3):475-489. [Crossref]  [PubMed]